IL6 and Alzheimer disease: We examined the effect of GRN allele status at rs5848 and TMEM106B variants rs1020004, rs1990622, and rs6966915 on PGRN or IL-6 plasma levels in control subjects (n = 133), AD (n = 82), and FTLD cases, excluding mutations in MAPT, GRN, and C9ORF72 (n = 184), but no significant correlations were seen either for FTLD overall or when stratified according to clinical diagnostic or genetic subgroup (see online Supplementary Tables 1–4).